Theranostics relies on a sophisticated combination of molecular imaging, radiopharmaceuticals, and companion diagnostics. Understanding the technology helps clinicians appreciate its capabilities and helps patients understand what to expect from treatment. In China, advances in these technologies are driving the growth of the theranostics market.

The foundation is molecular imaging, typically PET or SPECT, using radiotracers that bind to specific targets on cancer cells. For prostate cancer, PSMA PET imaging visualises prostate-specific membrane antigen. For neuroendocrine tumours, somatostatin receptor imaging is used. If imaging confirms target expression, the same molecule can be labelled with a therapeutic radioisotope and administered to deliver radiation directly to tumour cells. Companion diagnostics, including genomic testing, guide targeted therapies in oncology. Advances in radiotracer design, imaging technology, and radiochemistry are expanding capabilities. These developments are shaping the China Theranostics Market report.

For patients, this technology means more precise diagnosis and treatment. For clinicians, it means better tools. For manufacturers, it means opportunities for innovation. As technology advances, theranostics will become even more effective and accessible in China, improving outcomes for patients.

People Also Ask

What is PSMA PET imaging?
It is a PET scan that targets prostate-specific membrane antigen, used to detect prostate cancer and identify patients for PSMA-targeted therapy.

What are companion diagnostics?
They are tests that identify whether a patient is likely to benefit from a specific therapy, guiding treatment selection.

Tags: #Theranostics #MolecularImaging #ChinaHealthcare #MedicalTechnology #NuclearMedicine #Innovation